The Convergence of Biology and Technology: Enabling the Rise of Precision Medicine in Renal Diseases

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (15 May 2022) | Viewed by 2584

Special Issue Editors


E-Mail Website
Guest Editor
Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University "Aldo Moro", 70121 Bari, BA, Italy
Interests: systems biology; artificial intelligence; glomerulonephritis; kidney transplantation

E-Mail Website
Co-Guest Editor
Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, 70124 Bari, Italy
Interests: genomics; transcriptomics; diabetic nephropathy; kidney transplantation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

There has been a vast increase in the availability of therapeutic options in every field of medicine. The bulk of such plurality of interventions represents a major advance toward personalized medicine. However, the ultimate goal of individualizing patient treatments can only be achieved through a granular dissection of the phenotype and the identification of molecular signatures that can aid in the optimization of the therapeutic intervention.

To this end, great effort must be put to integrate multiple data modalities comprising-omics, medical records, and imaging in order to provide actionable insights based on precise patient profiles. In this Special Issue of the Journal of Personalized Medicine, we aim at highlighting the results of such an approach that leverages the convergence of the most advanced techniques in biology and technology, to show the progresses that have been made toward precision medicine in the field of renal medicine. The issue will emphasize the relevance of these findings that encompass all areas of nephrology, from acute kidney injury and glomerulonephritis to transplantation.

Dr. Francesco Pesce
Guest Editor

Dr. Paola Pontrelli
Co-Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Kidney diseases
  • Biomarkers
  • Genomics
  • Proteomics
  • Transcriptomics
  • Metabolomics
  • Epigenetics
  • Systems biology

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 10725 KiB  
Article
Clinical Mass Spectrometry Discovered Human IgG Sialylation as a Potential Biosignature for Kidney Function
by Chih-Chin Kao, San-Yuan Wang, Yung-Kun Chuang, Wei-Yuan Lee, Wei-Chiao Chang, Mai-Szu Wu, Tai-Chih Kuo and I-Lin Tsai
J. Pers. Med. 2021, 11(8), 761; https://doi.org/10.3390/jpm11080761 - 31 Jul 2021
Cited by 4 | Viewed by 2064
Abstract
Immunoglobulin G (IgG) N-glycosylation was discovered to have an association with inflammation status, which has the potential to be a novel biomarker for kidney diseases. In this study, we applied an ultra-high performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) method to plasma and urine [...] Read more.
Immunoglobulin G (IgG) N-glycosylation was discovered to have an association with inflammation status, which has the potential to be a novel biomarker for kidney diseases. In this study, we applied an ultra-high performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) method to plasma and urine samples from 57 individuals with different levels of kidney function. Natural abundances of total IgG, IgG1, IgG2, and IgG3 subclasses in plasma showed positive correlations to the estimated glomerular filtration rates (eGFRs). Eighteen IgG glycopeptides also showed positive correlations. In contrast, higher IgG amounts were found in urine samples from participants with lower eGFR values. After normalizing IgG glycopeptides from plasma to their respective protein amounts, H4N4F1S1-IgG1 (r = 0.37, p = 0.0047, significant) and H5N4F1S1-IgG1 (r = 0.25, p = 0.063, marginally significant) were the two glycopeptides that still had positive correlations with eGFRs. The results showed that the UHPLC-MS/MS method is capable of investigating IgG profiles, and monitoring IgG and glycosylation patterns is worthy of further clinical application for kidney disease. Full article
Show Figures

Figure 1

Back to TopTop